CARMAT Inactive Instrument
Carmat Share Price Other OTC
Equities
Medical Equipment, Supplies & Distribution
| Sales 2023 | 2.8M 3.04M 253M | Sales 2024 * | 14.85M 16.13M 1.34B | Capitalization | 103M 112M 9.34B |
|---|---|---|---|---|---|
| Net income 2023 | -53M -57.57M -4.79B | Net income 2024 * | -38M -41.28M -3.43B | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.91M 4.48B | Net Debt 2024 * | 61.25M 66.53M 5.53B | EV / Sales 2024 * | 11.1 x |
| P/E ratio 2023 |
-3.09
x | P/E ratio 2024 * |
-2.2
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 01/16/01 |
Alain Carpentier
FOU | Founder | 91 | 25/08/25 |
| Director of Finance/CFO | - | 12/18/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22/22/22 |
| Director/Board Member | 85 | 12/16/12 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 05/18/05 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
30/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +12.05% | 128B | |
| -9.24% | 10.88B | |
| +0.29% | 8.76B | |
| +36.99% | 5.48B | |
| -21.98% | 4.72B | |
| +8.02% | 3.43B | |
| -10.32% | 2.76B | |
| -12.33% | 2.06B | |
| -13.53% | 1.92B |
